Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Research and development expenses for the third quarter of 2025 were $14.0 million, compared with $11.6 million for the third quarter in 2024. The increase was primarily due to additional costs ...
Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide ...
Today on GMN we dive into part two of our four-part series with financial expert Barry Bigelow on how to start a new business ...
Tribune Online on MSN
China’s five-year planning model, lessons for Nigeria’s development — Envoy
The Chinese Ambassador to Nigeria, Yu Dunhai, has said that China’s system of five-year planning model has not only sustained the country’s rapid transformation but also offers valuable lessons for ...
Adjusted basic and diluted net income per ADS attributable to KE Holdings Inc.’s ordinary shareholders 11 were RMB1.17 (US$0.16) and RMB1.12 (US$0.16) in the third quarter of 2025, respectively, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback